Pazopanib is Both Effective and Well Tolerated in Metastatic Soft Tissue Carcinoma, Study Shows

A multicenter retrospective study has results revealed that treatment with pazopanib is both effective and well-tolerated in good performance status patients with relapsed, advanced nonadipocytic soft tissue sarcomas.

Photo: Disease Attacking A Human Cell | InStyleHealth


Experts evaluated real-life data of single-agent pazopanib efficacy and safety for soft tissue sarcomas in the Turkish population. There was a total of 103 patients, where 62 were females, who received pazopanib for advanced nonadipocytic soft tissue sarcomas in eight centers in Turkey were evaluated all together.

An 800 mg dose of pazopanib were administered to patients once a day. Results measured included progression-free survival, overall survival, and adverse events.

Among the analyzed patients with median age of 50 years old, with age ranges from 38-58, 41% of whom had leiomyosarcoma. The median progression-free survival was 4.3 months, and the median overall survival was 10.1 months. Common toxicities recorded were fatigue, anorexia, weight loss, nausea, and hypertension; grade >3 toxicities included fatigue, anorexia, weight loss, and liver disorder.

Earlier study showed that pazopanib may cause cardiotoxicity such as heart failure, which can be fatal in some patients. Doctors and patients are urged to be aware of such risk when managing the use of pazopanib in soft tissue sarcoma.

According to experts, soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency. Pazopanib is an orally available multi-tyrosine kinase inhibitor that was explored in patients with nonadipocytic advanced soft tissue sarcomas.

 

Source: J Oncol Pharm Pract 2021;27:541-546

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post